China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary China Resources Zizhu passed the generic drug quality and efficacy consistency evaluation of China's medical products regulator for propranolol hydrochloride injection.
The drug treats arrhythmias, angina and pheochromocytoma, according to a Thursday filing with the Shanghai bourse.